OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Clinical Oncology is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Tasadenoturev active in DIPG	1090
A new standard of care for advanced-stage urothelial carcinoma	746
From little subclones grow mighty oaks	745
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma	717
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC	629
Hodgkin lymphoma: great progress with room for improvement	623
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes	595
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC	577
Novel ICI–TKI combination improves HCC outcomes	565
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care	542
The immune landscape of common CNS malignancies: implications for immunotherapy	533
Gut microbiota in colorectal cancer development and therapy	528
Current understanding and management of CAR T cell-associated toxicities	524
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime	480
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials	480
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety	448
The emerging roles of circRNAs in cancer and oncology	438
From ESMO 2022	437
From the ESMO Congress 2021	386
Mortality is similar with active monitoring	340
Ponatinib superior to imatinib in Ph+ ALL	337
Contrasting results with second-line CAR T cells in large B cell lymphoma	337
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence	335
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC	334
Sacituzumab tirumotecan improves OS in mTNBC	328

Adjuvant immunotherapy for NSCLC — does treating earlier mean treating better?	319
Humanized mouse models for immuno-oncology research	313
Minimal residual disease as a target for liquid biopsy in patients with solid tumours	300
Predicting cancer outcomes with radiomics and artificial intelligence in radiology	285
Harnessing cytokines and chemokines for cancer therapy	284
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours	277
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response	277
Craniospinal irradiation improves leptomeningeal metastasis control	257
Survival benefit with second-line combination in endometrial cancer	245
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs	245
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease	244
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer	224
Biomarkers for immunotherapy of hepatocellular carcinoma	210
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship	206
Improving outcomes in patients with oesophageal cancer	202
Harnessing big data to characterize immune-related adverse events	200
Spatial landscapes of cancers: insights and opportunities	199
Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070	198
DREAMseq of therapy for BRAF-mutant melanoma	195
Approvals in 2022: overall survival, dose optimization, new approvals and beyond	195
New CAPSTONE of SCLC therapy?	194
SHINE a light: frontline ibrutinib for MCL	191
Amivantamab is effective in NSCLC harbouring EGFR exon 20 insertions	191
Women with clinically node negative breast cancer can safely avoid axillary surgery	188
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC	188
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC	181
Aumolertinib is effective in NSCLC	172
Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond	171
From ESMO 2023: advances in lung cancer	166
Mitigating acute chemotherapy-associated adverse events in patients with cancer	158
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	158
Circulating tumour DNA — looking beyond the blood	151
Targeting chromosomal instability in patients with cancer	147
Long-term outcomes following CAR T cell therapy: what we know so far	143
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC	140
Benefit with ramucirumab in mesothelioma	139
Response to neoadjuvant endocrine therapy complements recurrence score	134
Multiomics STEP up in correlative analysis of response to CAR T cells	131
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress	130
From the ESMO Congress 2023	129
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM	116
HAIC-FO improves outcomes in HCC	113
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas	113
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma	110
Newly approved cancer drugs in China — innovation and clinical benefit	109
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL	108
Claudin 18.2 as a novel therapeutic target	107
Lung cancer in patients who have never smoked — an emerging disease	106
Enhancing immunotherapy with tumour-responsive nanomaterials	106
Clinical implications of T cell exhaustion for cancer immunotherapy	104

From the 2021 ASCO Annual Meeting	99
HCL — vemurafenib plus rituximab holds promise	97
Targeted biopsy reduces detection of clinically insignificant cancer	97
Combining CAR T cells effective in RRMM	95
Two decades of advances in clinical oncology — lessons learned and future directions	90
Translating biological insights into improved management of endometrial cancer	86
Author Correction: Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	86
Less-frequent surveillance is noninferior to annual mammography	83
Barriers in access to oncology drugs — a global crisis	81
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy	81
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges	78
BrECADD raises the bar in classical Hodgkin lymphoma	77
HSCT prolongs remission of high-risk CTCLs	76
Nirogacestat effective in desmoid tumours	74
Promise with co-administration of CAR T cells	73
Tabelecleucel is effective in EBV-positive lymphoproliferative disease	71
GPRC5D-CAR T cells active in MM	69
Efficacy of TILs confirmed	69
Promising OS with oncolytic virotherapy	69
Thermal ablation is safer than resection of colorectal liver lesions	68
Uncovering adagrasib resistance	67
Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood	64
Exploiting bacteria for cancer immunotherapy	62
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome	59
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer	58
The current state of the art and future trends in RAS-targeted cancer therapies	57
Repotrectinib effective in ROS1-fusion-positive NSCLC	55
Neoadjuvant pembrolizumab improves outcomes	54
177Lu–PSMA-PET extends survival	52
MSI-H/dMMR mCRC: ICIs in the first line?	52
Pembrolizumab tunes up chemotherapy in cervical cancer	51
Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes	50
Belzutifan is active in VHL-related cancers	49
LAG3 inhibition improves outcomes	47
Author Correction: Anaplastic glioma: benefit of temozolomide clarified	47
KN046 shows tolerability and activity in TNBC	46
Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?	46
Problematic crossovers in cancer drug trials	45
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	42
The emerging roles of γδ T cells in cancer immunotherapy	41
CAR T cells induce durable remission of neuroblastoma	41
Integrated MRI-guided radiotherapy — opportunities and challenges	41
Venetoclax–obinutuzumab combinations are effective in fit patients with CLL	40
Author Correction: EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment	40
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges	40
National value-based pricing negotiation for oncology drugs — lessons from China	34
Axicabtagene effective in indolent NHL	33
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma	32
GPRC5D as a novel immunotherapeutic target in multiple myeloma	30
Personalizing adjuvant therapy for patients with colorectal cancer	30
Therapeutic targeting of the hypoxic tumour microenvironment	30
Laparoscopic TME is non-inferior	29
Personalizing the approach to neoadjuvant therapy: a promising path to improving outcomes of resectable melanoma	29